Visual and anatomical outcome after intravitreal bevacizumab injection for myopic CNV
| Outcome | Baseline (32 eyes) | 3 months (32 eyes) | 12 months (32 eyes) | 24 months (32 eyes) | 36 months (27 eyes) |
| BCVA (No of ETDRS letters) | 30.1±15.6 | 41.5±11.8 | 46.5±11.1 | 46.6±12.4 | 45.4±13.0 |
| p Value | <0.0001* | <0.0001* | <0.0001* | <0.0001* | |
| BCVA change (No of ETDRS letters) | 11.4±9.3 | 16.4±10.1 | 16.5±11.9 | 16.5±12.4 | |
| Range, min:max | −3:36 | −3:38 | −15:44 | −10:42 | |
| CNV area (mm2) | 0.63±0.71 | 0.36±0.57 | 0.32±0.46 | 0.33±0.47 | 0.40±0.57 |
| p Value | <0.0001* | <0.0001* | <0.0001* | <0.0001* | |
| CNV closure rate (%) | 25/32 (78%) | 30/32 (94%) | 27/27 (100%) | ||
| No of injections | 4.1±1.7 | 1.1±1.9 | 0.5±1.0 | ||
| Range, min:max | 3:8 | 0:6 | 0:3 |
Values are mean±SD unless otherwise indicated.
↵* Student t test for paired data.
BCVA, best corrected visual acuity; CNV, choroidal neovascularisation; ETDRS, Early Treatment Diabetic Retinopathy Study.